Overcoming resistance to HER2-directed ADCs in HER2+ breast cancer

Dr. Hamilton on Overcoming Resistance to HER2-Targeted Therapy in Breast CancerПодробнее

Overcoming resistance to trastuzumab deruxtecan in HER2-low cancersПодробнее

Advances in novel ADCs for HER2-expressing breast cancerПодробнее

Combination therapies incorporating ADCs in breast cancerПодробнее

Insights into mRNA expression in ADC targets in metastatic breast cancerПодробнее

Overcoming Resistance in ER+ Breast CancerПодробнее

Resistance to ADCs in breast cancer and novel combination strategiesПодробнее

Emerging strategies to overcome resistance to HER2 ADCs in breast cancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее

Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapyПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

Dr. Hurvitz on Using ADCs in HER2+ Breast CancerПодробнее

ADCs for HER2+ and HER2-low breast cancerПодробнее

The latest clinical research on ADCs in breast cancerПодробнее

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast CancerПодробнее

ADCs for the treatment of HER2-low breast cancerПодробнее

Antibody-drug conjugates for the treatment of breast cancerПодробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее